What the future holds for second medical use patents

Described by legal commentators as “the case of year”, and with numerous interim issues decided, English judge Mr Justice Arnold and the Court of Appeal have already grappled with a number of issues in Warner-Lambert (Pfizer) v Actavis and Mylan & Actavis v Warner-Lambert leading up to the decision of Arnold on September 10, 2015 on infringement and validity respectively.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

Explainer: ARIPO’s role in Plant Variety Protection

15 July 2025 Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization.

Africa

Commercialising genomic tech in Nigeria

29 April 2025 Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.

Africa

J&J pledges not to enforce TB patents in certain countries

3 October 2023 Non-profit hails move but urges other big pharma companies to follow suit | To avoid litigation, manufacturers must ensure generic versions are of good quality, medically acceptable, and are used only in the selected low-and middle-income countries.

More features

Insulin pump rivals face off in major trade secrets dispute hearing

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

Who are the world’s best in-house counsel? Final call for the leading corporate IP professionals

Arnold & Porter loses another regulatory partner to growing rival

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Merchant & Gould hires 13 attorneys to open new Boston office

Novo Nordisk secures China win ahead of key patent expiration

Edwards v Meril: Inside the UPC’s landmark medtech showdown

What the future holds for second medical use patents

More on this story

Editor's picks

Editor's picks

More features